Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQGS: DAWN) TO SERVIER. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF DAY ONE WILL RECEIVE $21.50 IN CASH FOR EACH SHARE OF DAY ONE THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS THAT LED TO IT ARE ADEQUATE,.

DAY ONE INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DAY ONE BIOPHARMACEUTICALS, INC. - DAWN

INSIDERS MAY STAND TO RECEIVE SUBSTANTIAL FINANCIAL BENEFITS NOT AVAILABLE TO ORDINARY SHAREHOLDERS. THE PROPOSED TRANSACTIONS MAY CONTAIN TERMS THAT COULD LIMIT SUPERIOR COMPETING OFFERS.

ARE DAWN AND TALK OBTAINING FAIR DEALS FOR THEIR SHAREHOLDERS?

SURESNES, FRANCE AND BRISBANE, CALIF., MARCH 06, 2026 (GLOBE NEWSWIRE) -- SERVIER, AN INDEPENDENT INTERNATIONAL PHARMACEUTICAL GROUP GOVERNED BY A FOUNDATION, AND DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED THAT THEY HAVE ENTERED INTO A DEFINITIVE AGREEMENT FOR SERVIER TO ACQUIRE DAY ONE FOR $21.50 PER SHARE IN CASH, REPRESENTING A TOTAL EQUITY VALUE OF APPROXIMATELY $2.5 BILLION. THE TRANSACTION REMAINS SUBJECT TO CUSTOMARY CLOSING CONDITIONS AND IS EXPECTED TO CLOSE IN THE SECOND QUARTER OF 2026.

SERVIER AND DAY ONE BIOPHARMACEUTICALS ANNOUNCE ACQUISITION TO EXPAND SERVIER'S RARE ONCOLOGY PORTFOLIO

OJEMDA 2025 MOMENTUM REFLECTED BY Q4 AND FULL YEAR NET PRODUCT REVENUES OF $52.8 MILLION AND $155.4 MILLION, RESPECTIVELY 2026 U.S. NET PRODUCT REVENUE PROJECTED AT $225 - $250 MILLION EXPANDED PIPELINE WITH JANUARY 2026 ACQUISITION OF MERSANA THERAPEUTICS; EMI-LE IN PHASE 1 TRIAL FOR ADENOID CYSTIC CARCINOMA (ACC) DAY ONE TO HOST CONFERENCE CALL AND WEBCAST TODAY, FEBRUARY 24, 4:30 P.M. ET BRISBANE, CALIF.

DAY ONE REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND REAFFIRMS 2026 OUTLOOK AND REVENUE GUIDANCE

BRISBANE, CALIF., FEB. 10, 2026 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST ON TUESDAY, FEBRUARY 24, 2026 AT 4:30 P.M.

DAY ONE TO REPORT FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS TUESDAY, FEBRUARY 24, 2026

PRELIMINARY 2025 NET PRODUCT REVENUE OF $155.4 MILLION, REPRESENTING 172% YEAR-OVER-YEAR GROWTH; OJEMDA 2026 U.S. NET PRODUCT REVENUE PROJECTED TO BE $225 - $250 MILLION COMPANY TO PRESENT ON CORPORATE PROGRESS AND PRIORITIES FOR 2026 DURING J.P. MORGAN HEALTHCARE CONFERENCE, JANUARY 12TH AT 5:15 PM PT (8:15 PM ET) BRISBANE, CALIF.

DAY ONE ANNOUNCES PRELIMINARY 2025 OJEMDA NET PRODUCT REVENUE AND PROVIDES 2026 NET PRODUCT REVENUE GUIDANCE

BRISBANE, CALIF., JAN. 06, 2026 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED THE SUCCESSFUL CLOSE OF ITS ACQUISITION OF MERSANA THERAPEUTICS, INC., (NASDAQ: MRSN) (MERSANA) FOLLOWING COMPLETION OF ALL CONDITIONS OF THE TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF MERSANA AT A PRICE OF $25 PER SHARE IN CASH, PLUS ONE NON-TRADABLE CONTINGENT VALUE RIGHT (CVR) PER SHARE TO RECEIVE CERTAIN POTENTIAL MILESTONE PAYMENTS OF UP TO AN AGGREGATE OF $30.25 PER CVR IN CASH.

DAY ONE COMPLETES ACQUISITION OF MERSANA THERAPEUTICS

BRISBANE, CALIF., DEC. 16, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED THAT DR. JEREMY BENDER, CHIEF EXECUTIVE OFFICER, WILL PRESENT DURING THE 44TH ANNUAL J.P.

DAY ONE TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

UPDATED DATA EXPANDS CLINICALLY MEANINGFUL RESULTS AVAILABLE FROM FIREFLY-1 PIVOTAL TRIAL 77% OF PATIENTS WHO ENTERED THE TREATMENT-FREE OBSERVATION PERIOD FOLLOWING OJEMDA TREATMENT REMAINED OFF THERAPY FOR AT LEAST 12 MONTHS THE MEDIAN TIME TO NEXT TREATMENT (TTNT) FOLLOWING INITIATION OF OJEMDA EXCEEDED 3.5 YEARS  BRISBANE, CALIF., NOV. 24, 2025 (GLOBE NEWSWIRE) -- DAY ONE BIOPHARMACEUTICALS, INC. (NASDAQ: DAWN) (DAY ONE OR THE COMPANY), A BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING AND COMMERCIALIZING TARGETED THERAPIES FOR PEOPLE OF ALL AGES WITH LIFE-THREATENING DISEASES, TODAY ANNOUNCED THREE-YEAR RESULTS FROM THE OJEMDA PIVOTAL PHASE 2 FIREFLY-1 TRIAL IN AN ORAL PRESENTATION AT THE 30TH ANNUAL MEETING & EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY.

DAY ONE ANNOUNCES THREE YEAR FOLLOW-UP DATA FROM OJEMDA (TOVORAFENIB) PHASE 2 FIREFLY-1 TRIAL AT THE 2025 SOCIETY FOR NEURO-ONCOLOGY (SNO) ANNUAL MEETING

Day One Biopharmaceuticals, Inc.

DAWN

Price

Financial Reports

No items found.

Press Releases

Day One Biopharmaceuticals, Inc.

DAWN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

DAWN